.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,376,479

« Back to Dashboard

Details for Patent: 6,376,479

Title: Method for treating and preventing hyperparathyroidism
Abstract:A method for reducing or preventing elevated blood parathyroid hormone level in a human being suffering from primary hyperparathyroidism, secondary hyperparathyroidism, or hyperparathyroidism secondary to end stage renal disease by administering a sufficient amount of 1.alpha.,24(S)-(OH).sub.2 vitamin D.sub.2.
Inventor(s): Knutson; Joyce C (Madison, WI), Bishop; Charles W. (Madison, WI)
Assignee: Bone Care International, Inc. (Middleton, WI)
Filing Date:Feb 09, 2000
Application Number:09/501,093
Claims:1. A method for lowering or maintaining lowered serum parathyroid hormone in human patients suffering from hyperparathyroidism, comprising: administering to said patients an effective amount of 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 to lower and maintain lowered serum parathyroid hormone levels.

2. The method of claim 1 wherein the hyperparathyroidism is primary hyperparathyroidism.

3. The method of claim 1 wherein the hyperparathyroidism is secondary hyperparathyroidism.

4. The method of claim 1 wherein the hyperparathyroidism is secondary to end stage renal disease.

5. The method of claim I wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered orally.

6. The method of claim 5 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 1 .mu.g to about 300 .mu.g.

7. The method of claim 5 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 30 .mu.g to about 200 .mu.g.

8. The method of claim 1 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is co-administered with a calcium phosphate binder.

9. The method of claim 1 wherein said 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in combination with at least one agent characterized by said agent's ability to reduce loss of bone mass, or bone mineral content in patients.

10. The method of claim 9 wherein said agent is other vitamin D compounds, conjugated estrogens, sodium fluorides, biphosphonates, cobalamin, pertussin toxin or boron.

11. The method of claim 1, wherein the administration of 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is parenteral.

12. The method of claim 11 wherein said administration is by intravenous injection, nasopharyngeal or mucosal absorption, or transdermal absorption.

13. The method of claim 11 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 1 .mu.g to about 150 .mu.g.

14. The method of claim 11 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 30 .mu.g to about 100 .mu.g.

15. The method of claim 1 wherein the administration of 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is nonparenteral.

16. A method of treating a human to alleviate or prevent the pathological effects of hyperparathyroidism, wherein the method comprises orally administering to the human in need thereof 1.alpha.,24(S)-(OH).sub.2 -vitamin D.sub.2 in an amount sufficient to lower or maintain lowered serum parathyroid hormone levels in said human to thereby alleviate or prevent the effects.

17. The method of claim 16, wherein said serum parathyroid hormone levels are measured by blood serum level of parathyroid hormone over time after ingestion.

18. The method of claim 16 wherein the hyperparathyroidism is primary hyperparathyroidism.

19. The method of claim 16 wherein the hyperparathyroidism is secondary hyperparathyroidism.

20. The method of claim 16 wherein the hyperparathyroidism is hyperparathyroidism secondary to end stage renal disease.

21. A method for lowering or maintaining lowered serum parathyroid hormone in a human patient suffering from secondary hyperparathyroidism, comprising: administering to said patient an effective amount of 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 to lower and maintain lowered serum parathyroid hormone levels.

22. The method of claim 21 wherein the .alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered orally.

23. The method of claim 22 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 1 .mu.g to about 300 .mu.g.

24. The method of claim 21 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered parenterally.

25. The method of claim 24 wherein the 1.alpha.,24(S)-dihydroxyvitamin D.sub.2 is administered in a weekly dosage of about 1 .mu.g to about 150 .mu.g.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc